Survey of the Perceived Quality of Patient Care in a Radiation Oncology Service: Results From 2002-2011.
Eguiguren Bastida M, Minguez J, Blanco C, Urraca J, Querejeta A, Uranga I, Ciria J, Rodríguez G, Caffiero S, Guimon E. A.
Int. J. Radiat. Oncol. Biol. Phys. 2012; 84: 541-0. FI: 4.105 (Q1).
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Final Results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial.
Llombart-Cussac A, Ruiz A, Anton A, Barnadas A, Antolin S, Ales-Martínez JE, Álvarez I, Andres R, García Saenz JA, Lao J, Carrasco E, Cámara C, Casas I, Martín M.
Cancer. 2012; 118: 241-247. FI: 4.771 (Q1).
New imaging and molecular biomarkers to predict pathological response to bevacizumab-based treatment in neoadjuvant breast cancer.
García-Foncillas J, Plazaola A, Hernando B, Sánchez R, Álvarez I, Anton A, Martínez Del Prado P, Llombart A, Sherer S, López-vega jm.
Ann. oncol. 2012; 23: 82-83. FI: 6.425 (Q1).
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers.
Bastien RRL, Rodríguez-Lescure A, Ebbert MTW, Prat A, Munarriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Segui MA, Barley, Lee B, Kenneth M, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Anton A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.
BMC Med. Genomics. 2012; 5: -0. FI: 3.693 (Q2).
